Factor X (Stuart Factor)

Subscribe to Selected New Research on Factor X

321 relevant articles (6 outcomes, 23 trials/studies) found for this Bio-Agent

Description: Storage-stable glycoprotein blood coagulation factor that can be activated to factor Xa by both the intrinsic and extrinsic pathways. A deficiency of factor X, sometimes called Stuart-Prower factor deficiency, may lead to a systemic coagulation disorder.

Also Known As:

Stuart Factor; Stuart Prower Factor; Blood Coagulation Factor X; Factor X, Coagulation; X, Coagulation Factor; Autoprothrombin III; Coagulation Factor X; Stuart-Prower Factor; Blood-coagulation factor X

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Castellino, F J: 2 articles (01/2003 - 02/2000)
2.	Liang, Z: 2 articles (01/2003 - 02/2000)
3.	Rosen, E D: 2 articles (01/2003 - 02/2000)
4.	Pollard, Morris: 1 article (06/2008)
5.	Suckow, Mark: 1 article (06/2008)
6.	Hacihasanoglu, A: 1 article (06/2008)
7.	Kocak, M: 1 article (06/2008)
8.	Yilmaz, M: 1 article (06/2008)
9.	Kamocka, Malgorzata: 1 article (06/2008)
10.	Rosen, Elliot D: 1 article (06/2008)

Related Diseases

1.	Factor X Deficiency 01/01/2005 - "Genetic analysis of hereditary factor X deficiency in a French patient of Sri Lankan ancestry: in vitro expression study identified Gly366Ser substitution as the molecular basis of the dysfunctional factor X." 11/01/1988 - "Congenital factor X (Stuart-Prower factor) deficiency: a family study." 05/01/2009 - "Identification of a novel factor X deletion in combination with a missense mutation in the F10 gene - Genotype-phenotype correlation in a girl with severe factor X deficiency." 02/01/2008 - "Factor XDebrecen: Gly204Arg mutation in factor X causes the synthesis of a non-secretable protein and severe factor X deficiency." 02/01/2008 - "A viable mouse model of factor X deficiency provides evidence for maternal transfer of factor X." Order ALL the reference details at left...
2.	Amyloidosis 09/01/1993 - "We suggest that the possibility of a spontaneous factor X recovery must be considered when evaluating efficacy of therapeutic agents in amyloidosis." 12/07/1992 - "Initially, factor X infusion studies showed a normal recovery, but when amyloidosis became overt the recovery decreased to 0%. " 06/01/1988 - "A reproducible model for the study of factor X kinetics in AA amyloidosis." 03/15/2001 - "Of 368 consecutive patients with systemic AL amyloidosis evaluated at Boston Medical Center, 32 patients (8.7%) had factor X levels below 50% of normal. " 01/01/1994 - "[A deficiency of blood coagulation factor X in a female patient with primary generalized amyloidosis]" Order ALL the reference details at left...
3.	Hemorrhage 06/01/2009 - "Factor X (FX) deficiency is a rare, recessively inherited bleeding disorder representing 10% of all rare bleeding diseases and affecting 1 in every 1,000,000 people. " 04/01/2008 - "The cause of this severe hemorrhage was due to a specific factor X inhibitor. " 05/01/2007 - "These patients, lacking any pre-existing or family history of abnormal bleeding, developed cutaneous, mucosal, or gastrointestinal bleeding in the course of their disease without deficiency of clotting factor X or other factors; the activated partial thromboplastin time (aPTT) was prolonged in three out of the four cases. " 01/01/2005 - "Factor X (FX) deficiency is a rare bleeding disorder inherited as an autosomal recessive trait. " 11/15/2001 - "We report a novel mutation in Factor X (FX) gene which results in a phenotype without any bleeding tendency. " Order ALL the reference details at left...
4.	Venous Thrombosis (Deep-Vein Thrombosis) 04/01/2006 - "In conclusion, APTT-based assays, but not direct factor X activation-based assays, effectively detect the risk for venous thrombosis independent of FVL. " 06/01/2001 - "Factor X levels, polymorphisms in the promoter region of factor X, and the risk of venous thrombosis." 02/16/2007 - "This exosite is physiologically highly relevant for the recognition and inhibition of factor X/Xa by macromolecular substrates and provides a structural motif for the development of a new class of inhibitors for the treatment of deep vein thrombosis and angioplasty." 04/01/2006 - "One hundred ninety-seven subjects with a history of venous thrombosis and 211 controls were explored using 3 APCR assays, the original APTT-based assay (test A), an APTT-based assay with factor V depleted plasma pre-dilution (test B) and a direct factor X activation-based assay with the same pre-dilution (test C). " 05/01/2003 - "Factor X inhibitors are also being evaluated for use in the treatment of the acute coronary syndromes, pulmonary embolism and deep vein thrombosis. " Order ALL the reference details at left...
5.	Disease Susceptibility (Diathesis) 10/01/1979 - "A case of severe haemorrhagic diathesis due to acquired deficiency of factor X (both immunologically and in procoagulant activity) is presented. " 07/01/2004 - "The mutations in factor X, in this part of the world are most probably not the one, which would cause a severe bleeding diathesis." 01/01/2003 - "In utero transplantation of wild-type fetal liver cells rescues factor X-deficient mice from fatal neonatal bleeding diatheses." 12/01/1982 - "From these experiments, it is inferred that normal activation of factor X in plasma due to dilute thromboplastin requires factors VII, IX and VIII. An alternative extrinsic pathway that involves factors VII, IX, and VIII may be a major physiologic extrinsic pathway, and this pathway may help to explain the clinical observations of bleeding diatheses in patients deficient in factors IX or VIII." 02/01/2008 - "Due to a homozygous Gly204Arg mutation in the factor X (FX) gene no detectable FX antigen was found in the plasma of a one-year old patient with severe bleeding diathesis. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Fibrinogen (Factor I)
2.	Thrombin
3.	Thromboplastin (Tissue Factor)
4.	prothrombin complex concentrates (PPSB)
5.	Dacarbazine (DIC)
6.	Amyloid (Amyloid Fibrils)
7.	Prothrombin (Factor II)
8.	Antithrombin III
9.	Protein C
10.	cancer procoagulant

Related Therapies and Procedures

1.	Splenectomy
2.	Angioplasty (Angioplasties)
3.	Transplantation (Transplant Recipients)
4.	Plasma Exchange
5.	Subcutaneous Injections

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>